Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents (Q38893086)

6 October 2017

1 reference

title

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents (English)

1 reference

6 October 2017

4

Dirk Schadendorf

1 reference

6 October 2017

Jeffrey S Weber

1

1 reference

6 October 2017

Michael Postow

series ordinal

2

1 reference

6 October 2017

Christopher D Lao

series ordinal

3

1 reference

6 October 2017

8 July 2016

1 reference

6 October 2017

1 reference

6 October 2017

21

1 reference

6 October 2017

10

1 reference

6 October 2017

1230-1240

1 reference

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Pembrolizumab versus Ipilimumab in Advanced Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Nivolumab in NSCLC: latest evidence and clinical potential

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Nivolumab in previously untreated melanoma without BRAF mutation

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061539

10.1634/THEONCOLOGIST.2016-0055

17 June 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference

6 October 2017

PubMed publication ID

27401894

1 reference